Vertex Pharmaceuticals Incorporated Share Price and Company Fundamentals
Last traded: Last Friday at 8:00 PM
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
|Industry / Sector||Biotechnology / Healthcare|
|Full time employees||3400|
|Mailing address||50 Northern Avenue Boston MA 02210 United States|
|Phone / Fax||617 341 6100 /|
Vertex Pharmaceuticals Incorporated does not pay dividends.
As of Aug 2021, following are the company executives and directors listed on Vertex Pharmaceuticals Incorporated.
|Dr. Jeffrey Marc Leiden M.D., Ph.D.||Exec. Chairman||64||3.14M|
|Dr. Reshma Kewalramani||CEO, Pres & Director||47||3.86M|
|Mr. Charles F. Wagner Jr.||Exec. VP & CFO||52||1.71M|
|Mr. Stuart A. Arbuckle||EVP, Chief Commercial & Operations Officer||54||2.03M|
|Dr. David M. Altshuler||Exec. VP of Global Research & Chief Scientific Officer||55||1.81M|
|Ms. Kristen Ambrose||Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services||44|
|Mr. Mike Tirozzi||SVP and Chief Information & Data Officer|
|Mr. Michael Partridge||Sr. VP of Investor Relations|
|Mr. Damian W. Wilmot Esq.||Sr. VP, Chief Risk and Compliance Officer||44|
|Ms. Joy Liu||Sr. VP & Gen. Counsel|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Vertex Pharmaceuticals Incorporated is 52.23B and its enterprise value is 46.09B. The enterprise value to revenue ratio of VRTX is 6.90.
The VRTX's stocks Beta value is 0.66 making it 34% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Frequently Asked Questions
1. What is Vertex Pharmaceuticals Incorporated's Stock Symbol?
Vertex Pharmaceuticals Incorporated trades on NASDAQ under the ticker symbol "VRTX".
2. What is Vertex Pharmaceuticals Incorporated's stock price today?
One share of VRTX stock can currently be purchased for approximately $201.58.
3. How can I contact Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated's mailing address is 50 Northern Avenue Boston MA 02210 United States. The company can be reached via phone at 617 341 6100.
4. What is Vertex Pharmaceuticals Incorporated's official website?
The official website of Vertex Pharmaceuticals Incorporated is http://www.vrtx.com.